Immunomedics, Inc. (Nasdaq: IMMU) announced first patient dosing in the Company's Phase III registration study of its pancreatic cancer drug ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE